A detailed history of Northern Trust Corp transactions in Vor Biopharma Inc. stock. As of the latest transaction made, Northern Trust Corp holds 380,743 shares of VOR stock, worth $266,520. This represents 0.0% of its overall portfolio holdings.

Number of Shares
380,743
Previous 398,362 4.42%
Holding current value
$266,520
Previous $944,000 59.75%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.0 - $2.2 $17,619 - $38,761
-17,619 Reduced 4.42%
380,743 $380,000
Q1 2024

May 14, 2024

BUY
$1.8 - $2.85 $2,053 - $3,251
1,141 Added 0.29%
398,362 $944,000
Q4 2023

Feb 13, 2024

BUY
$1.66 - $2.63 $75,994 - $120,401
45,780 Added 13.03%
397,221 $893,000
Q3 2023

Nov 13, 2023

BUY
$2.1 - $3.35 $1,442 - $2,301
687 Added 0.2%
351,441 $745,000
Q2 2023

Aug 11, 2023

BUY
$3.09 - $5.33 $874,834 - $1.51 Million
283,118 Added 418.59%
350,754 $1.08 Million
Q1 2023

May 15, 2023

BUY
$4.68 - $6.96 $144,429 - $214,792
30,861 Added 83.92%
67,636 $363,000
Q4 2022

Feb 13, 2023

BUY
$3.77 - $7.43 $51,471 - $101,441
13,653 Added 59.05%
36,775 $244,000
Q3 2022

Nov 14, 2022

BUY
$3.9 - $5.52 $15,974 - $22,609
4,096 Added 21.53%
23,122 $92,000
Q2 2022

Aug 12, 2022

SELL
$3.89 - $6.44 $489,910 - $811,060
-125,941 Reduced 86.88%
19,026 $94,000
Q1 2022

May 13, 2022

SELL
$6.04 - $12.23 $42,032 - $85,108
-6,959 Reduced 4.58%
144,967 $875,000
Q4 2021

Feb 08, 2022

SELL
$11.32 - $18.02 $12,735 - $20,272
-1,125 Reduced 0.74%
151,926 $1.77 Million
Q3 2021

Nov 15, 2021

BUY
$12.24 - $20.38 $514,973 - $857,447
42,073 Added 37.91%
153,051 $2.4 Million
Q2 2021

Aug 13, 2021

SELL
$18.65 - $38.78 $204,702 - $425,649
-10,976 Reduced 9.0%
110,978 $2.07 Million
Q1 2021

May 12, 2021

BUY
$30.96 - $54.08 $3.78 Million - $6.6 Million
121,954 New
121,954 $5.26 Million

Others Institutions Holding VOR

About Vor Biopharma Inc.


  • Ticker VOR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,056,300
  • Market Cap $26.6M
  • Description
  • Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AM...
More about VOR
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.